Autres langues Denali Therapeutics Inc.

Actions

DNLI

US24823R1059

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
15,43 ^USD	+3,14%		-3,56%	-28,10%

09/04	DENALI THERAPEUTICS INC. : UBS toujours positif	ZM
03/04	Un initié de Denali Therapeutics a vendu des actions pour une valeur de 1 896 250 $, selon un récent dépôt auprès de la SEC	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	09/04
Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing	03/04
Denali Therapeutics Files Prospectus for Secondary Offering	22/03
Denali Therapeutics Inc. announced that it has received $499.73271 million in funding from Baker Bros. Advisors LP and other investors	01/03
Denali Shares Rise on PIPE Deal, Plan to Spin Out Preclinical Small Molecule Portfolio	27/02
Denali Q4 Net Loss Widens; Launching PIPE Deal, Plans to Spin Out Preclinical Small Molecule Portfolio; Shares Jump Pre-Bell	27/02
Denali Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	27/02
Denali Therapeutics Announces $500 million Private Placement Equity Financing	27/02
Denali Therapeutics Announces $500 million Private Placement Equity Financing	27/02
Denali Therapeutics Inc. announced that it expects to receive $499.73271 million in funding from Baker Bros. Advisors LP and other investors	27/02
North American Morning Briefing : S&P 500 Futures -2-	23/02
Sanofi Informs Denali That Potential ALS Drug Misses Primary Endpoint of Phase 2 Study	20/02
Denali Therapeutics Shares Fall After ALS Treatment Misses Primary Endpoint	16/02
Sanofi : échec d'un essai de phase 2 contre la SLA	16/02
Denali Therapeutics Insider Sold Shares Worth $402,420, According to a Recent SEC Filing	16/02
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™	07/02
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™	07/02
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier-Crossing Enzyme Replacement Therapy Programs At Worldsymposium	07/02
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™	01/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Denali Therapeutics Inc.

Actions

DNLI

US24823R1059

Autres langues

Filtres